Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Tintinger, Gregory Ronald | |
dc.contributor.author | Feldman, Charles | |
dc.contributor.author | Theron, Annette J. | |
dc.contributor.author | Anderson, Ronald | |
dc.date.accessioned | 2012-05-23T08:28:11Z | |
dc.date.available | 2012-05-23T08:28:11Z | |
dc.date.issued | 2010-12-14 | |
dc.description.abstract | The prototype cysteinyl leukotriene receptor antagonist, montelukast, is generally considered to have a niche application in the therapy of exercise- and aspirin-induced asthma. It is also used as add-on therapy in patients whose asthma is poorly controlled with inhaled corticosteroid monotherapy, or with the combination of a long-acting β(2)-agonist and an inhaled corticosteroid. Recently, however, montelukast has been reported to possess secondary anti-inflammatory properties, apparently unrelated to conventional antagonism of cysteinyl leukotriene receptors. These novel activities enable montelukast to target eosinophils, monocytes, and, in particular, the corticosteroid-insensitive neutrophil, suggesting that this agent may have a broader spectrum of anti-inflammatory activities than originally thought. If so, montelukast is potentially useful in the chemotherapy of intermittent asthma, chronic obstructive pulmonary disease, cystic fibrosis, and viral bronchiolitis, which, to a large extent, involve airway epithelial cell/neutrophil interactions. The primary objective of this mini-review is to present evidence for the cysteinyl leukotriene–independent mechanisms of action of montelukast and their potential clinical relevance. | en_US |
dc.description.uri | http://www.thescientificworld.com | en_US |
dc.identifier.citation | Tintinger, G.R., Feldman, C., Theron, A.J., and Anderson, R. (2010) Montelukast: more than a cysteinyl leukotriene receptor antagonist? TheScientificWorldJOURNAL 10, 2403–2413. DOI 10.1100/tsw.2010.229. | en_US |
dc.identifier.issn | 1537-744X | |
dc.identifier.other | 10.1100/tsw.2010.229 | |
dc.identifier.uri | http://hdl.handle.net/2263/18834 | |
dc.language.iso | en | en_US |
dc.publisher | Hindawi Publishing Corporation | en_US |
dc.rights | © 2010 with author. | en_US |
dc.subject | Chronic obstructive pulmonary disease | en_US |
dc.subject | Cyclic AMP | en_US |
dc.subject | Cysteinyl leukotrienes | en_US |
dc.subject | Cystic fibrosis | en_US |
dc.subject | Histone acetyltransferase | en_US |
dc.subject | 5-lipoxygenase | en_US |
dc.subject | Cyclic nucleotide phospodiesterase | en_US |
dc.subject | Sepsis | en_US |
dc.subject | Viral bronchiolitis | en_US |
dc.title | Montelukast : more than a cysteinyl leukotriene receptor antagonist? | en_US |
dc.type | Article | en_US |